You are here: Home: Audio Program Guide: BCU 7 | 2006 Audio: BCU 7 | 2006
 
  Go to interview with Mark D Pegram, MD
Go to interview with Victor G Vogel, MD, MHS
Go to interview with Debu Tripathy, MD
Go to interview with Robert W Carlson, MD



 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Mark D Pegram, MD
Associate Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Women’s Cancer Program
UCLA/Jonsson Comprehensive Cancer Center
Los Angeles, California		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Case discussion: A 68-year-old woman with HER2-positive, ER-positive, node-negative breast cancer averse to receiving chemotherapy
Track 3 Counseling patients about the benefits of adjuvant chemotherapy
Track 4 Estimating the risk of relapse for patients with HER2-positive, ER-positive, node-negative disease
Track 5 Utility of the Oncotype DX™ assay for treatment decision-making in HER2-positive and HER2-negative disease
Track 6 Relative benefit of chemotherapy, hormonal therapy and trastuzumab for patients with HER2-positive, ER-positive disease

Track 7 Clinical use of trastuzumab monotherapy in combination with hormonal therapy
Track 8 Adjuvant trastuzumab for patients with small node-negative tumors
Track 9 Selection of adjuvant hormonal therapy based on HER2 status
Track 10 Biologic rationale for combining trastuzumab with fulvestrant
Track 11 Delayed adjuvant trastuzumab
Track 12 Concurrent versus sequential use of adjuvant chemotherapy and trastuzumab
Track 13 Role of quantitative amplification of HER2 by FISH in treatment decision-making
Track 14 Concordance between community and reference laboratories in FISH testing
Track 15 Use of FISH versus immunohistochemistry
Track 16 Selection of a chemotherapeutic regimen to combine with adjuvant trastuzumab
Track 17 Topoisomerase II-alpha (TOPO II) gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy: BCIRG 006

Track 18 Dose-dense AC paclitaxel with trastuzumab
Track 19 Selection of adjuvant chemotherapy for patients with HER2-negative, node-positive disease
Track 20 Prophylactic growth factor support with TAC chemotherapy
Track 21 Docetaxel/cyclophosphamide (TC) versus AC
Track 22 FinHER: Adjuvant docetaxel or vinorelbine with or without trastuzumab
Track 23 Importance of protocol-defined cardiac monitoring in clinical practice

Track 24 Counseling patients about the risk of cardiotoxicity and cardiac follow-up after completion of therapy with trastuzumab
Track 25 Current clinical trials evaluating the safety and efficacy of bevacizumab in breast cancer
Track 26 Thromboembolic and cardiac side effects of bevacizumab
Track 27 Potential role of lapatinib in the adjuvant setting
Track 28 Potential role of cMYC amplification as a predictor of response to trastuzumab
     
Victor G Vogel, MD, MHS
Director, Magee/UPCI Breast Cancer Prevention Program
Professor of Medicine and Epidemiology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Development of the Oncotype DX assay
Track 3 Clinical use of Oncotype DX to assist in the selection of adjuvant therapy
Track 4 Utility of the Oncotype DX assay for patients with HER2-positive disease
Track 5 Case discussion: A woman with a 1.2-cm, ER-positive, node-negative breast tumor and a high Oncotype recurrence score
Track 6 Predictability of Oncotype recurrence score based on classic clinical factors

Track 7 Applicability of Oncotype recurrence score for patients with large tumors
Track 8 Side effects of tamoxifen versus aromatase inhibitors
Track 9 Use of bisphosphonates to prevent aromatase inhibitor-associated bone loss and fractures
Track 10 Duration of adjuvant hormonal therapy
Track 11 NSABP-P-4: Letrozole versus raloxifene for the prevention of breast cancer
Track 12 Clinical use of aromatase inhibitors for ductal carcinoma in situ
Track 13 NSABP-P-2: Study of Tamoxifen and Raloxifene (STAR) for the prevention of breast cancer
Track 14 Tolerability of raloxifene versus tamoxifen in the STAR trial
Track 15 Acceptance of tamoxifen by women at high risk for breast cancer
Track 16 Importance of discussing adherence with patients receiving adjuvant hormonal therapy
     
Debu Tripathy, MD
Professor of Internal Medicine
Director, Komen UT Southwestern Breast Cancer Research Program
University of Texas Southwestern Medical Center
Dallas, Texas		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 BCIRG 006: Adjuvant AC followed by docetaxel (T) versus AC followed by T and trastuzumab (H) versus TCH
Track 3 Counseling patients about the risk of cardiac toxicity associated with chemotherapy and trastuzumab
Track 4 Clinical use of trastuzumab as monotherapy or with single-agent chemotherapy
Track 5 Concurrent versus sequential use of chemotherapy and trastuzumab
Track 6 Potential role of TOPO II and cMYC amplification as predictors of response

Track 7 Time course for initiating delayed adjuvant trastuzumab
Track 8 Clinical use of dose-dense AC paclitaxel and trastuzumab
Track 9 Future directions for adjuvant clinical trials in HER2-positive disease
Track 10 Potential use of trastuzumab in combination with epirubicin to mitigate cardiotoxicity
Track 11 Continuation of trastuzumab after disease progression
Track 12 Clinical use of bevacizumab
Track 13 Role of metronomic chemotherapy in the management of metastatic disease
Track 14 Efficacy, tolerability and benefits of nanoparticle albumin-bound (nab) paclitaxel
Track 15 Clinical use of the Oncotype DX assay
Track 16 ECOG-E1199: Adjuvant AC followed by paclitaxel or docetaxel, given every three weeks or weekly
     
Robert W Carlson, MD
Professor of Medicine
Division of Oncology and Stanford Medical Informatics
Stanford University Medical Center
Stanford, California		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Selection of up-front adjuvant hormonal therapy
Track 3 Divergent perspectives on the role of aromatase inhibitors as adjuvant therapy
Track 4 Selection of adjuvant endocrine therapy based on HER2 and PR status
Track 5 Management of patients with ER-positive disease who become amenorrheic after chemotherapy
Track 6 Ovarian suppression plus an aromatase inhibitor in premenopausal women

Track 7 Clinical use of fulvestrant in patients with ER-positive metastatic disease
Track 8 Variability of the effectiveness of LHRH agonists in suppressing ovarian function
Track 9 Utilization of the Oncotype DX assay for patients with small, node-negative, ER-positive tumors
Track 10 Adjuvant TC versus AC
Track 11 Prophylactic growth factor support with TAC and dose-dense chemotherapy
Track 12 Selection of adjuvant chemotherapy for patients with ER-positive, node-positive disease
Track 13 Clinical use of dose-dense AC with growth factor support
Track 14 Capecitabine as first-line therapy for patients with asymptomatic metastatic disease
Track 15 Incorporation of bevacizumab into clinical practice
Track 16 Rationale for the greater use of capecitabine by clinical research leaders than by community-based physicians
Track 17 Combining bevacizumab with other chemotherapeutic agents
Track 18 Use of TOPO II in clinical decision-making regarding adjuvant trastuzumab and chemotherapy
Track 19 Selection of patients for treatment with adjuvant trastuzumab